RG7604 is primarily utilized in the field of oncology as a targeted therapeutic agent. It functions by inhibiting specific pathways involved in cancer cell proliferation and survival, making it effective in treating certain types of cancers. The compound is often employed in clinical trials to evaluate its efficacy and safety in patients, particularly those with resistant or advanced forms of cancer. Its mechanism of action allows it to selectively target cancer cells while minimizing damage to healthy tissues, thereby reducing side effects commonly associated with traditional chemotherapy. Additionally, RG7604 is being studied for its potential in combination therapies, where it may enhance the effectiveness of other anticancer drugs.